Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology SA (CYAD) has appointed Dr. Marina Udier to its Board of Directors. Dr. Udier, a highly regarded leader in biopharmaceuticals, is expected to leverage her extensive experience in advancing the company’s CAR T therapy pipeline. CEO Filippo Petti expressed confidence in her ability to strengthen Celyad's position in the CAR T space. Dr. Udier previously served as CEO of Nouscom and held senior roles at Novartis. Celyad continues to focus on developing a robust pipeline for treating hematological malignancies and solid tumors, supported by funding from the Walloon Region in Belgium.
Celyad Oncology has entered a committed equity purchase agreement with Lincoln Park Capital for up to $40 million. Over 24 months, Celyad can direct LPC to purchase American Depositary Shares, with a maximum regular purchase of $2.5 million. LPC's purchase price will be determined by the lower of the lowest sale price on the purchase date or the average of the three lowest closing prices in the preceding ten days. The proceeds will support the company's research and development of CAR T cell therapies. Celyad ended 2020 with a treasury position of €17.2 million, sufficient to fund operations into Q3 2021.
Celyad Oncology SA (CYAD), a clinical-stage biotechnology firm, will participate in multiple conferences in January 2021. The H.C. Wainwright BioConnect Conference is scheduled for January 11-14, with a dedicated webcast available on January 11. Following this, Celyad will present at the Keystone eSymposia on January 25. The company is focused on developing CAR T therapies for cancers and has received funding from the Walloon Region of Belgium to advance its projects. Further details can be found on their official website.
Celyad Oncology SA (NASDAQ: CYAD) announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, designed for refractory metastatic colorectal cancer. Preliminary data is expected in the first half of 2021. Dr. Eric Van Cutsem noted the historical challenges CAR T therapies faced in solid tumors, while Celyad's CYAD-101 aims to improve clinical outcomes using a non-gene edited, allogeneic CAR-T strategy. The trial will assess the safety and efficacy of CYAD-101 with FOLFIRI chemotherapy.
Celyad Oncology has announced significant updates regarding its CAR T candidates. The first patient has been dosed with CYAD-211 in the Phase 1 IMMUNICY-1 trial, indicating a key milestone in developing therapies for refractory multiple myeloma. Preclinical results show strong antitumor activity without Graft-versus-Host Disease. Meanwhile, the company has discontinued development of CYAD-01 due to clinical futility observed in the Phase 1 THINK trial. Encouraging initial results for CYAD-02 were reported in the ongoing CYCLE-1 trial.
Celyad Oncology has initiated the Phase 1 IMMUNICY-1 trial, dosing its first patient with CYAD-211, an innovative CAR T therapy targeting BCMA for relapsed/refractory multiple myeloma. The trial will assess safety and efficacy across various dose levels. The company secured €3.4 million in non-dilutive funding from SPW-Recherche to support CYAD-211's development. Preliminary data from the trial is anticipated in the first half of 2021, aiming to address the high unmet need for effective treatments in multiple myeloma.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that CEO Filippo Petti will participate in a fireside chat at the virtual JMP Securities Hematology Summit on December 16, 2020, at 10:00 a.m. ET / 4:00 p.m. CET. A live and archived webcast will be available on the company's website. Celyad Oncology focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, with a pipeline of allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Founded in 2007, the company is based in Mont-Saint-Guibert, Belgium and New York, NY.
Celyad Oncology (CYAD) provided a business update for Q3 2020, emphasizing advancements in its clinical pipeline. Key highlights include a partnership with MSD for a Phase 1b trial of CYAD-101 combined with KEYTRUDA in metastatic colorectal cancer (mCRC) patients. The company is set to initiate the IMMUNICY-1 trial for CYAD-211 by year-end 2020, targeting relapsed/refractory multiple myeloma. As of September 30, 2020, Celyad reported a cash position of €20 million ($23.4 million) and a net cash burn of €6.7 million ($7.8 million), confirming sufficient funds through Q3 2021.
Celyad Oncology (CYAD) announced that three abstracts were accepted for presentation at the 62nd American Society of Hematology Annual Meeting, occurring virtually from December 5-8, 2020. The abstracts will focus on the company’s CAR T candidates: the allogeneic CYAD-211 targeting BCMA, and the autologous CYAD-01 and CYAD-02 based on the NKG2D receptor. The findings will be published in the November issue of the journal Blood. CYAD-211 has received FDA clearance for its IND application, representing progress in CAR T therapy development for multiple myeloma and related cancers.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced its participation in three upcoming healthcare conferences in November 2020. The events are: Bryan, Garnier & Co. Virtual European Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17 at 2:55 p.m. ET, and SVB Leerink Oncology 1x1 Day on November 19. The company focuses on developing CAR T therapies for cancer, supported by the Walloon Region funding. Investors can find more details on Celyad's website.
FAQ
What is the market cap of CYAD (CYAD)?
